The Henry Schein FastPass guarantees an elevated experience with immense educational value at DS World 2024. Transform your dental practice by engaging with cutting-edge insights during our educational sessions, offering up to 8.5 CE credits. Additionally, an exclusive 90-minute session will captivate with a range of thrilling topics, including the impact of connected technology on dental practices.

Beyond immersive education, DS World offers unforgettable enjoyment. After a full day of learning, unwind with exclusive shows and create lasting memories at Caesars Forum. The All Access FastPass, available for $699, includes everything the Exhibit Only FastPass offers, plus back-to-back evenings of entertainment.

For an elevated experience, the VIP FastPass at $1,699 provides an express registration line, priority seating at general sessions and evening entertainment, access to the VIP Lounge in the exhibit hall, 4 drinks tickets to be used during the evening entertainment, a Dentsply Sirona branded gift, and more.

The Exhibit Only FastPass can be upgraded to the All Access FastPass or the VIP FastPass during registration.

Click here for more information.

Click here or the image for more information.

• Jefferies Global Healthcare Conference at Marriott Marquis, New York, on June 5, at 10:00 AM ET
• Goldman Sachs Global Healthcare Conference at Loews Miami Beach Hotel, Miami, on June 11, at 11:20 AM ET

Henry Schein’s presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts.

Replays will be available on the Henry Schein website following the presentations.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with over 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.3 billion in 2023 and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

• Bank of America Healthcare Conference at Encore Resort, Las Vegas, on May 14, at 4:20 PM Pacific time, 7:20 PM Eastern time
• Leerink Healthcare Crossroads Conference at Omni Barton Creek Hotel, Austin, on May 29, at 11:20 AM Central time, 12:20 PM Eastern time
• Stifel Jaws & Paws Conference at St. Regis Hotel, New York City, on May 30, at 10:20 AM Eastern time

Henry Schein’s presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on X.

FEATURED IMAGE CREDIT: BoliviaInteligente on Unsplash.

GORG includes the Company’s comprehensive portfolio of premium value and value implant lines and a full range of biomaterial products. HSG includes a range of company-owned manufacturing brands in the high-growth endodontic, orthodontic, and orthopedic markets.

“We are delighted to welcome three strong and proven leaders to the Henry Schein Executive Management Committee,” said Stanley Bergman, Chairman and Chief Executive Officer of Henry Schein, Inc. “Steve, Bianka, and Tom have each demonstrated vision and commitment in inspiring and leading our teams to excellence in a quickly changing global healthcare marketplace. Our senior leadership team will benefit greatly from the added perspectives of these seasoned professionals.”

The GORG and HSG businesses are central to advancing the Company’s BOLD+1 strategic plan, in particular, the building of higher-growth and higher-margin specialty products and services offerings that complement our distribution, software, and value-added businesses. Together, the Company is leveraging these businesses to broaden and deepen relationships with customers.

Mr. Boggan joined Henry Schein in 2013 with the Company’s acquisition of BioHorizons, which he joined as a start-up in 1995 and has led as President and CEO since 1999. As Co-CEO of GORG, Mr. Boggan will lead commercial operations in North and South America and the Middle East as well as global marketing.

Ms. Wilson joined Henry Schein in 2018 after a successful 25-year career in finance and consulting. Prior to Henry Schein, she served as Group CFO of Ascom Holding AG, a Swiss public company in the medical communication technology sector, and, prior to that, as Advisory and Global Account Lead Partner at KPMG. Ms. Wilson had been serving as Chief Financial Officer of GORG, and, as Co-CEO, she will lead strategy, finance, and human resources as well as the group’s business in Europe and APAC.

Mr. Popeck joined Henry Schein in 2019 with more than 20 years of sales leadership and general management experience, including extensive experience in the medical device sector. Prior to joining Henry Schein, he spent over two decades leading businesses in orthopedics and industrial manufacturing, including spending 11 years at Stryker, where he held various leadership roles, including leading Stryker’s Foot & Ankle business unit as Vice President and General Manager. In 2023, he was promoted to President of Henry Schein’s Healthcare Specialties Group.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.

Investors can access the call by visiting https://investor.henryschein.com/webcasts.

A replay will be available on the Henry Schein website following the presentation.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS and Adjusted EBITDA guidance and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, , financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; geopolitical wars; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

FEATURED IMAGE CREDIT: Happy Stock Photo/Shutterstock.com.

For the fourth consecutive year, THRIVELIVE will offer a comprehensive program designed to empower all dental professionals. This year’s event will provide unparalleled access to:

• Cutting-Edge Education: Gain insights and practical knowledge through a wide range of courses and workshops relevant to all aspects of dentistry, including software training, team development, health and wellness, hygiene protocols, business and practice management.
• Hands-on Technology Experience: Explore the latest dental technologies and equipment from leading manufacturers. Gain firsthand experience through interactive demonstrations to discover how these advancements can optimize practice workflows.
• Unveiling Henry Schein Solutions: Discover the unique suite of services, solutions, and products offered by Henry Schein, specifically designed to support a dental practice’s success.
• Networking Opportunities: Connect and collaborate with peers from across the dental field. Build valuable relationships and exchange knowledge, fostering a sense of community within the dental profession.

THRIVELIVE will include two General Sessions featuring prominent business and clinical leaders, more than 80 presentations, and 12 workshops offered to all attendees. These curated courses provide dental teams an opportunity to enhance their skills, knowledge, and capabilities to help drive better patient care and a more profitable office.

“As we celebrate the fourth year of delivering the THRIVELIVE experience, we are excited once again to bring together the best and brightest dental professionals and thought leaders to create a truly unique event for the entire dental team,” stated Mark Hillebrandt, chief digital revenue officer of Henry Schein. “At Henry Schein, our commitment remains unwavering, providing dental professionals with an unparalleled educational experience that equips each attendee with the latest knowledge and technologies, empowering every individual to make informed decisions about their practices.”

THRIVELIVE will also feature entertainment events included in the attendee’s ticket price, such as the “THRIVELIVE Bash” at Drai’s Night Club and “LIVE! @ THRIVELIVE,” headlined by renowned actor and comedian Ray Romano.

Additionally, this year THRIVELIVE will partner with TeamSmile, a non-profit organization that provides children in need an impactful dental experience through the power of sports, to bring awareness to and engage dental professionals in this mission.

To learn more about THRIVELIVE 2024, visit https://thrivelive2024.com/.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.3 billion in 2023, and have grown at a compound annual rate of approximately 11.5 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

The Midwinter Meeting, scheduled for February 22 to February 24, 2024, will provide practitioners with an opportunity to experience an immersive display of Henry Schein’s extensive range of products and solutions, aimed at empowering oral health professionals to elevate practice efficiency and enhance the overall patient experience.

Key highlights include:

• Software solutions covering practice management, marketing, patient engagement, and artificial intelligence (AI) from Henry Schein One (booth #3012);
• Merchandise products and exclusive offers on Henry Schein Brand Products (booth #3019);
• Transition planning, sales, valuations, and practice financing solutions from Henry Schein Dental Practice Transitions and Henry Schein Financial Services (booth #3019);
• Henry Schein’s Thrive brand programs and events, a portfolio of offerings that provide savings, rewards, support, and experiences designed to help enhance practice success (booth #3019); and
• Revenue cycle management offerings from eAssist Dental Solutions, including insurance reimbursement optimization from Unitas PPO solutions, and dental coding and administration resources from Practice Booster (booth #3019).

Throughout the meeting, Henry Schein will demonstrate the latest products and digital technology solutions, including scanners and 3D printers. Members of the Henry Schein Dental leadership team will be available to discuss products and solutions including: 3Shape Trios 5, Ackuretta CURIE Plus & SOL Printer, ACTEON C50 and SoproCare, Carina Sensors, Dentsply Sirona Primescan, Primemill, and Primeprint, DEXIS OP3D and IS3800, DigiDoc x90, Henry Schein Brands Reprocessing Bundle, Ivoclar CS6, Medit i700, Planmeca Emerald S and Planmill, SprintRay Ecosystem, and Vatech Green CT and PaX-i3D SMART.

“As Team Schein advances a human-centric approach in the digital landscape, we eagerly anticipate engaging with dental professionals at the Chicago Midwinter Meeting,” said Dave Steck, President, U.S. Dental Group, Henry Schein. “The meeting is a platform for us to highlight our extensive array of solutions and services, and to showcase how we contribute to enhancing the customer experience. Through our customer-centric approach, Henry Schein ensures that health care professionals can rely on us to consistently provide an experience that connects our wide array of offerings.”

Henry Schein One (booth #3012) will showcase the company’s integrated patient management platforms, including Dentrix and Dentrix Ascend®, and their accompanying suites. These suites directly integrate with each platform, spanning the workflows of the dentist’s office, inclusive of the services needed to ensure practice success:

• Revenue Cycle Management: Billing & Payments suite; Eligibilities & Claims Processing suite;
• Patient Experience: Dentrix & Dentrix Ascend Communications suites; Patient Forms; Patient Booking;
• Marketing: Digital Presence Suites (Sesame & Officite)
• Dental Analytics powered by Jarvis;
• Clinical: Detect AI, powered and manufactured by VideaHealth; Voice, powered by Bola AI; and
• Services: TechCentral for IT support; Dental Practice Consulting.

For more information about Henry Schein’s presence at the 2024 Chicago Dental Society Midwinter Meeting, please visit https://henryscheinevents.com/.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 Company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.6 billion in 2022, and have grown at a compound annual rate of approximately 12.1 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

With the unique ability to treat both Class II and Class III patients with one device, Carriere Motion Pro bite corrector features a custom-designed drop-in hook to enhance treatment versatility. The wider reinforced cuspid pad hook ensures a consistent distribution of elastic forces, while the hook’s deep undercut simplifies elastic engagements and effectively secures the Force Oral Elastics, a portfolio of products designed to work seamlessly with Motion appliances to provide optimal results. The latest addition to the portfolio, the Force 3 Elastics, will be available soon.

The new Carriere Motion Pro bite corrector also features a built-in scribe line, flat faces, straight edges, and a recessed dimple, helping to provide intuitive and accurate placement. This efficient design provides fast and predictable treatment, and the condyle shaped joint is designed to facilitate more natural and controlled movement.

“As Henry Schein Orthodontics continues to invest in innovative orthodontic products, we are pleased to announce the latest addition of the new Carriere Motion Pro,” said Christophe Carsault, vice president and general manager, Henry Schein Orthodontics. “Just as the original Motion appliance revolutionized the way many orthodontists approach sagittal correction, we are confident that the new CarriereMotion Pro will similarly advance orthodontics and help enhance our customers capabilities to achieve more efficient and predictable aligner and orthodontic treatment. We look forward to additional educational offerings and supporting our customers’ innovation to help them deliver a new standard of care with the Carriere Motion Pro.”

Like the Carriere Motion Pro, the original Motion appliances were created by Dr. Luis Carrière, who also popularized the SAGITTAL FIRST philosophy, an approach to care that helps standardize, simplify, and shorten Class II and Class III treatment time by treating the AP dimension at the beginning of treatment².

“I’m happy to introduce the Carriere Motion Pro as a solution of honest and sophisticated design driven to maximize treatment efficiency and precision as well as patient comfort with an absolute ease of use,” said Dr. Luis Carrière.

To learn more about the Carriere Motion Pro bite corrector, please visit Motion Pro | Henry Schein Orthodontics (henryscheinortho.com), email USASales@HenryScheinOrtho.com, or call (760) 448-8600.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.6 billion in 2022, and have grown at a compound annual rate of approximately 12.1 percent since Henry Schein became a public company in 1995.

REFERENCES

1. Motion Pro bite corrector patent pending. Not available in all countries. See your local distributor for more information.
2. Data on file
3. Coming soon

Henry Schein’s presentations can be heard via a live webcast by visiting https://investor.henryschein.com/webcasts.

Replays will be available on the Henry Schein website following the presentations.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

A FORTUNE 500 company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.6 billion in 2022, and have grown at a compound annual rate of approximately 12.1 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

Carole T. Faig (Photo: Business Wire)

Ms. Faig brings extensive expertise in finance, audit, and public accounting, with particular experience in the healthcare sector, including hospitals, health insurance, biotechnology, and medical device companies. Prior to her retirement in July 2021, concluding her 38-year career at Ernst & Young LLP (EY), Ms. Faig held various leadership roles.

These included U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY’s strategy to grow its healthcare practice in a rapidly changing environment. Ms. Faig holds a Bachelor of Business Administration in accounting from Sam Houston State University and is a certified public accountant.

“We are pleased to welcome Carole to our Board. Her proven expertise in navigating the transformation of health care and her deep accounting experience will be valuable assets as we advance the strategic goals of the Company. We expect Carole will bring new perspectives that will enhance the effectiveness of our Board, and we look forward to her contributions to Henry Schein’s continued success,” said Stanley M. Bergman, chairman of the board and chief executive officer of Henry Schein.

Ms. Faig is currently a member of the boards of directors of three companies, where she serves as the Audit Committee Chair: Cue Health, a Nasdaq-listed company, and Affinia Therapeutics and QuVa Pharma, private equity–backed private businesses. A champion for diversity, she served on EY’s Gender Equity Task Force and was awarded EY’s Chairman’s Value Award and Americas Assurance Inclusive Leadership Award in recognition of her commitment to building an inclusive workplace.

“It is a pleasure to join the Board of Henry Schein and be part of a team actively shaping the future of health care amidst a rapidly evolving health ecosystem,” said Ms. Faig. “Henry Schein’s commitment to providing innovative health care solutions and to be a trusted advisor and consultant to our customers is truly inspiring. I look forward to leveraging my expertise to support our continued growth and impact.”

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with over 300 valued solutions that help improve operational success and clinical outcomes. Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently, enabling them to provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, offering a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

A FORTUNE 500 Company and a member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.6 billion in 2022, growing at a compound annual rate of approximately 12.1 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and Twitter.com/HenrySchein.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that could cause future results to differ materially from the forward-looking statements, expectations, and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, and achievements or industry results to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make,” or other comparable terms. A fuller discussion of our operations, financial condition, and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our most recently filed Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Forward-looking statements include the impact of the cybersecurity incident on our business and results of operations, including the accuracy of our estimates of the impact, the timing and extent of any insurance claim recovery, the overall impact of the Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”) products and COVID-19 related product sales and inventory levels, whether additional resurgences or variants of the virus will adversely impact the resumption of normal operations, whether supply chain disruptions will adversely impact our business, the impact of integration and restructuring programs as well as of any future acquisitions, general economic conditions including exchange rates, inflation and recession, and more generally current expectations regarding performance in current and future periods. Forward-looking statements also include (i) our ability to have continued access to a variety of COVID-19 test types, and COVID-19 vaccines and ancillary supplies, and (ii) expectations regarding COVID-19 test sales, demand and inventory levels.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance, cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the healthcare industry; risks from the expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macroeconomic and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to healthcare fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; litigation risks; new or unanticipated litigation developments and the status of litigation matters; risks associated with customs policies or legislative import restrictions; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.